Company Overview
Atrium Therapeutics, Inc. operates as a biopharmaceutical company dedicated to delivering ribonucleic acid (RNA) therapeutics specifically to the heart to transform care for individuals living with cardiomyopathies. The company focuses its development efforts on product candidates such as ATR 1072, which is an siRNA-based therapy targeting PRKAG2. This entity functions within the Healthcare sector and the Biotechnology industry, positioning itself to address unmet medical needs through advanced molecular interventions. The company currently holds a market capitalization of $205.26M and reported annual revenue of $18.62M for the trailing twelve months, while the employee count is not disclosed in available data. These financial figures indicate that the company is a small-cap entity operating with limited revenue scale, which is typical for biotechnology firms in the development stage that prioritize capital expenditure on research and development over immediate profitability or large-scale commercial sales.
Financial Health
The company reported revenue of $18.62M, a net income of $-49,501,000, and an EBITDA of $-49,308,000 for the trailing twelve months. The substantial gap between the relatively modest revenue of $18.62M and the significant net loss of $49,501,000 reveals a cost structure where operating expenses, likely driven by research, development, and administrative costs, far exceed the revenue generated from current sales. Free cash flow stands at $-11,653,375, indicating that the company is burning cash to fund its operations and development pipeline, which limits immediate financial flexibility and necessitates ongoing access to capital markets or existing reserves. When analyzing profitability margins, the gross margin is recorded at -137.8%, the operating margin is -3387.9%, and the profit margin is -265.9%, all of which indicate that the company is currently operating at a loss at every level of the income statement due to high upfront costs and low revenue realization. Regarding the balance sheet, total cash is not disclosed (N/A) while total debt stands at $3.67M, and the debt-to-equity ratio is not available; however, the presence of debt alongside a lack of disclosed cash reserves suggests a reliance on equity financing rather than leverage. The current ratio is 0.07, which indicates that the company's current assets are only a fraction of its current liabilities, pointing to significant short-term liquidity challenges and potential difficulties in meeting obligations without raising new capital. Furthermore, the return on equity is not available, while the return on assets is -399.2%, revealing that management has not yet generated positive returns on the assets invested in the business, reflecting the high-risk nature of early-stage biotechnology development.
Valuation Assessment
The trailing P/E ratio is not available (N/A) due to the lack of positive earnings, whereas the forward P/E is listed as -3.28, implying that the market is pricing in future profitability that has not yet been realized or that the valuation model relies on projected earnings that differ significantly from historical performance. The price-to-book ratio is -3.27, which indicates that the market values the company at a negative multiple of its book value, a common characteristic for biotechnology companies with significant intangible assets or R&D investments that are not fully captured on the balance sheet. The price-to-sales ratio is 11.02, suggesting that investors are willing to pay a premium relative to sales, while the EV/EBITDA is not available; these alternative metrics suggest that traditional valuation multiples based on earnings are insufficient for assessing this asset, and investors must rely on revenue or asset-based metrics instead. The 52-week high is $16.77 and the 52-week low is $11.95, meaning the stock has experienced significant volatility over the past year within this specific price range. Without a specific current price provided in the facts, the precise percentage deviation cannot be calculated, but the range demonstrates a trading band of approximately $4.82, reflecting the speculative nature of the stock. The beta is not available, which precludes an assessment of the stock's volatility relative to the broader market based on historical price movements.
Growth & Income
Revenue growth year-over-year is -71.1%, while earnings growth is not available (N/A), indicating that the company is experiencing a contraction in top-line sales rather than expansion. Because earnings are not positive, they cannot grow faster than revenue; instead, the negative revenue growth suggests a decline in commercial activity or a shift in the business model that has impacted sales figures. The company does not pay a dividend, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available resources or retains all earnings into growth initiatives rather than distributing income to shareholders. Consequently, the overall growth and income profile for Atrium Therapeutics, Inc. is characterized by significant revenue contraction, negative cash flow, and a lack of income generation, relying entirely on future clinical successes or market uptake to reverse the current negative trajectory.